Melphalan Macure

Melphalan, the active ingredient in Melphalan Macure, is an alkylating agent presented as an injectable solution for intravenous use. It is employed in the treatment of multiple myeloma, ovarian cancer, malignant melanoma, and other solid tumors in adult patients, where it helps to control disease progression.

GNH USA supplies Melphalan Macure as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Melphalan is an alkylating chemotherapy agent used in several solid‑tumor indications.

- Multiple myeloma: reduces malignant plasma cell proliferation and improves survival outcomes. - Ovarian cancer: used as part of combination regimens to achieve tumor shrinkage. - Malignant melanoma: administered in selected cases to control disease spread. - Other solid tumors: employed where evidence supports benefit, often in conjunction with other cytotoxic drugs.

Melphalan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Fatigue: persistent tiredness affecting daily activities. - Myelosuppression: decreased white blood cells, red cells and platelets leading to anemia, infection risk and bleeding. - Mucositis: inflammation and ulceration of the oral mucosa.

Serious or Rare Side Effects: - Secondary acute leukemia: emergence of a new hematologic malignancy after prolonged exposure. - Severe infection (sepsis): life‑threatening bacterial or fungal infections due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis presenting with cough and dyspnea.

When using Melphalan, clinicians should observe several precautionary measures to minimize toxicity and ensure safe handling.

- Monitor blood counts: perform regular complete blood count tests to detect myelosuppression early. - Assess renal function: adjust therapy if creatinine clearance is reduced. - Evaluate hepatic function: liver impairment may alter drug metabolism. - Avoid use in patients with known hypersensitivity to melphalan or related nitrogen‑mustard agents. - Use effective contraception: both male and female patients should employ reliable birth control during treatment and for a defined period afterward. - Store at ambient temperature: keep the product in its original packaging, protect from light and moisture, and do not freeze.

Melphalan may interact with other medicines, influencing its efficacy or toxicity profile.

Major Interactions (Avoid): - Live vaccines: concurrent administration can lead to uncontrolled infection due to immunosuppression. - Other alkylating agents: combined use markedly increases risk of severe myelosuppression and organ toxicity.

Moderate Interactions (Monitor Closely): - Antiemetic agents (e.g., ondansetron): may require dose adjustment to manage nausea without affecting melphalan clearance. - Granulocyte‑colony stimulating factors (G‑CSF): used to mitigate neutropenia but should be timed to avoid overlapping peak toxicity. - Anticoagulants (e.g., warfarin): melphalan can potentiate bleeding risk; monitor coagulation parameters.